Navigation Links
Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
Date:3/11/2010

Important Safety Information

Do not take Lupron Depot if any type of allergic reaction to Lupron Depot or similar drugs has been experienced.

Lupron Depot 7.5 mg, – three-month 22.5 mg and – four-month 30 mg should not be used in women.

An increase in testosterone will generally occur during the first few weeks of therapy. In some men, this may cause a temporary increase in urinary symptoms and/or pain. Men with cancer that has spread to the spine or urinary tract may require close medical attention during the first few weeks of therapy.  Men should also know that Lupron Depot may cause impotence.

The doctor should be notified if any new or worsened symptoms develop after beginning Lupron Depot treatment.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Ga., Feb. 26, 2015  MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental ... the fourth quarter and full year ended December 31, ... 2014 Highlights , Full Year 2014 ...
(Date:2/26/2015)... 26, 2015  PDL BioPharma, Inc. (PDL or the Company) ... will hold its annual meeting of stockholders on Thursday, May ... of record on April 2, 2015. The meeting will take ... Village, Nevada . About PDL BioPharma PDL ... its Queen et al. patents, license agreements with various biotechnology ...
(Date:2/26/2015)... MnM Conferences is pleased to ... place on the 27 - 28 April 2015 and will ... . Leading academics, scientists and business development ... world will be travelling to the Nanotechnologies in Drug ... capitalists and other financiers looking to invest in their ...
Breaking Medicine Technology:MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 2MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 3MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 4MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 5MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 6MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 7MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 8MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 9MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 10MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 11MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 12MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 13MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 14MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 15MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 16MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 17MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 18PDL BioPharma to Hold Annual Meeting of Stockholders on May 28, 2015 2MnM Conferences Announces Their Inaugural Congress - Nanotechnologies in Drug Delivery 2MnM Conferences Announces Their Inaugural Congress - Nanotechnologies in Drug Delivery 3
... May 16, 2011 For the second year in a row, ... recognized Eveo Communication Group ( www.eveo.com ) as ... advanced another front in the annual A d ... 25 Healthcare Agency list for the first time. (Photo: ...
... May 16, 2011 Telik, Inc. (Nasdaq: TELK ... March 31, 2011.  The net loss for the quarter ended ... a net loss of $5.3 million, or $0.10 per share, for ... development expenses (R&D) in the first quarter of 2011 were ...
Cached Medicine Technology:Eveo Ranked #1 Independent Digital Healthcare Agency in U.S. 2nd Year in a Row 2Telik Announces First Quarter 2011 Financial Results 2Telik Announces First Quarter 2011 Financial Results 3
(Date:2/26/2015)... In this episode of SCI ... Shadle discusses her study that searched for commonalities in ... Track and Field. Shadle wanted to explore the key ... impacted athletes’ success and helped win the Olympic gold. ... only critical to peak athletic performance but to any ...
(Date:2/26/2015)... When Cosmetic Town launched in 2012, its ... what will soon be, the cornerstone of work that ... of insight that will be accessible to the public, ... has maintained during its existence. Users have more data ... by visiting the Cosmetic Town Journal’s doctor’s page. There ...
(Date:2/26/2015)... Wound Care Advantage (WCA), ... its executive team by adding three key members possessing ... same time two WCA team members were promoted to ... was founded in 2002 and is one of the ... WCA team believes that providing outstanding patient care is ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 ... provider of advanced delivery technologies and development ... products, has today announced several expanded capabilities ... The expansions have been implemented in response ... packaging, where the proportion of highly-potent or ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 The ... reopening of their newly renovated office in Lawrenceville, NJ. ... Reproductive Science Center of New Jersey’s physicians, and NJ ... and patient care in the areas of infertility and ... for having excellent success rates and providing current, high ...
Breaking Medicine News(10 mins):Health News:Anne Shadle and Controlling the Olympic Moment on SCI TV 2Health News:Anne Shadle and Controlling the Olympic Moment on SCI TV 3Health News:Cosmetic Town has now Recreated Itself by Adding New Features 2Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 2Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 3Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 4Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 2Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3
... With swine flu topping the agenda of,business around ... maps and indices revealing the countries most at risk ... Influenza Pandemic Risk Index (IPRI) consists of three categories:,Risk ... Each index,generates a list of countries most at risk ...
... of people suffering from chronic sciatica was revealed ... placebo-controlled trial. Researchers from the Walter Reed ... of etanercept, a unique therapeutic that neutralizes TNF ... for sciatica. Epidural etanercept for sciatica was invented ...
... Kan., April 30 In 1918 a human influenza ... central United States while a swine respiratory disease occurred ... found that the virus causing the pandemic was able ... kill them, unlike in other mammalian hosts like monkeys, ...
... sclerosis treatment shows promise in study , , THURSDAY, April ... combination with a multiple sclerosis (MS) drug may give ... drug alone, suggests a new study. , In the ... patients were randomly selected to receive the steroid drug ...
... from the medical, scientific, and business arenas convened ... Medicine,s Spring 2009 Session. Held April 23-25th ... of Anti-Aging Medicine (A4M; www.worldhealth.net ), the ... enhancement and life extension that impacts more than ...
... Auction to Include Autographed Miley Cyrus Golf Car and a ... USC Mascot Traveler(R)BURBANK, Calif., April 30 ... celebrities, musicians, dancers and magnificent horses at the Los Angeles ... Spanish Horse extravaganza, all in support of raising funds ...
Cached Medicine News:Health News:Maplecroft Flu Pandemic Maps Reveal Countries Most at Risk 2Health News:New Hope for Relief of Chronic Sciatica 2Health News:New Hope for Relief of Chronic Sciatica 3Health News:K-State Researcher Finds That the 1918 Spanish Flu Virus Can Infect Swine and Resulted in Current Lineage of H1N1 Swine Influenza Viruses 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:World Anti-Aging Congress 2009 Defies Global Economic Downturn, Demonstrating Strength of Anti-Aging Medical Movement 2Health News:World Anti-Aging Congress 2009 Defies Global Economic Downturn, Demonstrating Strength of Anti-Aging Medical Movement 3Health News:World Anti-Aging Congress 2009 Defies Global Economic Downturn, Demonstrating Strength of Anti-Aging Medical Movement 4Health News:World Anti-Aging Congress 2009 Defies Global Economic Downturn, Demonstrating Strength of Anti-Aging Medical Movement 5Health News:Celebrities, Horses, Music and History Will Unite for 2009 'Fiesta of the Spanish Horse' Cancer Research Benefit 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
Medicine Products: